Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Fineline Cube Jul 10, 2026
Company Drug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Fineline Cube Jul 10, 2026
Company

Henlius’ Serplulimab Receives EU Approval for Extensive-Stage Small Cell Lung Cancer

Fineline Cube Feb 6, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) announced that it has received marketing approval from...

Company Drug

Harbour BioMed Receives NMPA Clearance for COPD Treatment HBM9378/SKB378

Fineline Cube Feb 6, 2025

China-based biopharmaceutical company Harbour BioMed (HKG: 2142) has announced receiving clinical clearance from China’s National...

Company Deals

Tofflon to Join Shanghai Biomedical M&A Fund with Leading Firms

Fineline Cube Feb 5, 2025

China-based Tofflon Science and Technology Group Co., Ltd. (SHE: 300171), a total solution service provider...

Company Deals

Becton Dickinson Considers Spinning Off Life Sciences Division

Fineline Cube Feb 5, 2025

US-based Becton, Dickinson and Co. (BD) is reportedly considering spinning off its life sciences division,...

Company Deals

Vantive Launches as Standalone Vital Organ Therapy Company Post Carlyle Acquisition

Fineline Cube Feb 5, 2025

Vantive, formerly the Baxter Kidney Care segment, has announced its launch as a new standalone...

Company Deals

Nona Biosciences Partners with Invetx for Animal Health Therapies

Fineline Cube Feb 5, 2025

Nona Biosciences (HKG: 2142), a wholly-owned subsidiary of HBM Holdings Ltd, has announced a partnership...

Company

AbbVie Reports Strong Q4 and Full-Year 2024 Financials

Fineline Cube Feb 5, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) has released its Q4 and full-year 2024 financial results,...

Company Drug

IASO Bio’s CAR-T Therapy Fucaso Accepted for Review in Singapore

Fineline Cube Feb 5, 2025

China-based IASO Biotherapeutics has announced that a New Drug Application (NDA) for its BCMA-targeted chimeric...

Company

Novartis Reports 12% YOY Growth in Full-Year Net Sales

Fineline Cube Feb 5, 2025

Swiss pharmaceutical major Novartis (NYSE: NVS) has released its Q4 and full-year 2024 financial report,...

Company

Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year

Fineline Cube Feb 5, 2025

Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has released its financial results for the 9-month period...

Company

Daiichi Sankyo Reports 16.6% Revenue Growth in First Three Quarters of FY2024

Fineline Cube Feb 5, 2025

Japan-based Daiichi Sankyo (TYO: 4568) has reported revenues of JPY 1.37 trillion ($8.927 billion) for...

Company

Pfizer Reports 7% Revenue Growth in 2024, Expects Steady Performance in 2025

Fineline Cube Feb 5, 2025

US major Pfizer Inc. (NYSE: PFE) has released its financial results for the fourth quarter...

Company Drug

China’s MoC Lists US Firms PVH and Illumina as Unreliable Entities

Fineline Cube Feb 5, 2025

China’s Ministry of Commerce (MoC) has released a list of unreliable entities, including US firms...

Company

Roche Reports 7% Growth in Full-Year Sales, Strength in Pharmaceuticals

Fineline Cube Feb 5, 2025

Swiss pharmaceutical giant Roche (SWX: ROG) released its Q4 and full-year 2024 financials, reporting a...

Company

Sanofi Reports Strong Q4 Growth, Plans EUR 5 Billion Share Buyback

Fineline Cube Feb 5, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) reported a strong fourth-quarter performance with 10.3% year-on-year (YOY)...

Company Deals

Xtalpi Partners with JW Pharmaceutical to Enhance Drug Discovery with AI

Fineline Cube Feb 5, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., a global leader in AI-powered...

Company

DeepSeek’s AI: Transforming Drug Development and Healthcare in China

Fineline Cube Feb 3, 2025

DeepSeek, a Chinese artificial intelligence company, is poised to make a significant impact on the...

Company Drug

MediLink Therapeutics’ YL217 Receives FDA IND Clearance for Novel ADC Targeting Gastrointestinal Cancers

Fineline Cube Feb 2, 2025

MediLink Therapeutics, a clinical-stage biotech company, announced today that its internally developed antibody-drug conjugate (ADC),...

Company

AbbVie’s 2024 Revenue Grows Despite Humira Decline, Skyrizi and Rinvoq Surge

Fineline Cube Feb 1, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) reported its 2024 financial results on January 31, with...

Company

PegBio’s Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment

Fineline Cube Jan 31, 2025

On January 28, 2025, the Hong Kong Stock Exchange (HKEX) website showed that PegBio Co.,...

Posts pagination

1 … 246 247 248 … 693

Recent updates

  • Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)
  • Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma
  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Jacobio Pharma’s Incubator Secures NMPA IND Clearance for JAR-2203 Injection – Novel Therapy Targeting Hyperlipoproteinemia(a)

Company Drug

Haixi Pharma Launches Phase III Trial of C019199 – First-in-Class Multi-Targeted Immunomodulator for Refractory Osteosarcoma

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.